APA (7th ed.) Citation

Javle, M., Borbath, I., Clarke, S., Hitre, E., Louvet, C., Macarulla, T., . . . Abou-Alfa, G. (2019). P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. Annals of Oncology, 30, iv62. https://doi.org/10.1093/annonc/mdz155.224

Chicago Style (17th ed.) Citation

Javle, M., et al. "P-225 - Phase 3 Multicenter, Open-label, Randomized Study of Infigratinib Versus Gemcitabine Plus Cisplatin in the First-line Treatment of Patients with Advanced Cholangiocarcinoma with FGFR2 Gene Fusions/translocations: The PROOF Trial." Annals of Oncology 30 (2019): iv62. https://doi.org/10.1093/annonc/mdz155.224.

MLA (9th ed.) Citation

Javle, M., et al. "P-225 - Phase 3 Multicenter, Open-label, Randomized Study of Infigratinib Versus Gemcitabine Plus Cisplatin in the First-line Treatment of Patients with Advanced Cholangiocarcinoma with FGFR2 Gene Fusions/translocations: The PROOF Trial." Annals of Oncology, vol. 30, 2019, p. iv62, https://doi.org/10.1093/annonc/mdz155.224.